$7.05
▲ +$0.03
(+0.43%)
Vol 1.7M
10
Quality Score
ok
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$916.3M
P/E
5.6
ROE
81.8%
Margin
75.8%
D/E
38.93
Beta
1.45
52W
$6–$17
Wall Street Consensus
13 analysts · Apr 20263
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
92.3%
Buy Rating
Price Chart
Similar Stocks
ESPR
Esperion Therapeutics Inc
$884.5M
LBRX
LB Pharmaceuticals Inc
$563.2M
ZVRA
Zevra Therapeutics Inc
P/E 14.3
$504.4M
FULC
Fulcrum Therapeutics Inc
$746.1M
ACRS
Aclaris Therapeutics Inc
$326.1M
AQST
Aquestive Therapeutics Inc
$788.1M
AVIR
Atea Pharmaceuticals Inc
$278.9M
CTNM
Contineum Therapeutics Inc
$417.5M
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.83 | $0.18 | $-0.65 |
| Sep 2025 | $0.66 | $1.26 | +$0.60 |
| Jun 2025 | $0.18 | $0.28 | +$0.10 |
| Mar 2025 | $0.27 | $0.30 | +$0.03 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $31.2M | $39.1M | $39.7M | $104.3M | $128.6M |
| Net Income | $13.5M | $20.6M | $19.8M | $108.6M | $14.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 42.7% | 42.7% | 42.7% | 42.7% | 81.8% | 81.8% |
| P/E (TTM) | 17.90 | 19.06 | 17.75 | 17.05 | 4.74 | 5.64 |
| Net Margin | 49.9% | 42.1% | 42.1% | 42.1% | 75.8% | 75.8% |
| Gross Margin | 95.3% | 95.6% | 95.6% | 95.6% | 92.6% | 92.6% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 38.93 | 38.93 |
| Current Ratio | 7.82 | 7.82 | 7.82 | 7.82 | 1.94 | 1.94 |
Key Ratios
ROA (TTM)
51.1%
P/S (TTM)
4.28
P/B
5.8
EPS (TTM)
$2.05
CF/Share
$-0.85
Rev Growth 3Y
+511.6%
52W High
$17.43
52W Low
$5.60
$5.60
52-Week Range
$17.43
Financial Health
Free Cash Flow
$92.7M
Net Debt
$4.1M
Cash
$144.8M
Total Debt
$148.9M
As of Dec 31, 2025
How does CRMD compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
CRMD valuation vs Pharmaceuticals peers
P/E ratio
5.6
▼
75%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
4.3
▼
14%
below
peers
(5.0)
vs Peers
vs Industry
Fair value
P/B ratio
5.8
▲
174%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
CRMD profitability vs Pharmaceuticals peers
ROE
81.8%
▲
251%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
75.8%
▲
260%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
92.6%
▲
36%
above
peers
(68.3%)
vs Peers
vs Industry
Below avg
ROA
51.1%
▲
236%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
CRMD financial health vs Pharmaceuticals peers
D/E ratio
38.9
▲
2428%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
1.9
▼
42%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
1.5
▲
54%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
CRMD fundamentals radar
CRMD
Peer median
Industry
CRMD profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CRMD vs peers: key metrics
Latest News
No related news yet